08:30 AM EDT, 07/02/2025 (MT Newswires) -- PharmaTher Holdings ( PHRRF ) , which is developing ketamine-based pharmaceuticals, on Wednesday confirmed that it is fully-funded right up to its initial U.S. commercial launch and it has no plans for new equity or debt financing.

The U.S. Food and Drug Administration has set a goal date of August 9, for the potential approval of PharmaTher's ( PHRRF ) ketamine product. The product will be manufactured in the United States, ensuring supply chain security, quality control, and readiness for commercial scale-up, a statement added.

PharmaTher ( PHRRF ) -- which saw its shares drop 6% last Monday, before the Canada Day holiday -- is preparing for international regulatory submissions in Europe, the United Kingdom, Canada, Japan, and the APAC regions, from the second half of this year.